Singapore devicemaker Biosensors International is handing over the rest of its business to the private equity arm of China's Citic Group for 1.1 billion Singapore dollars ($787 million), a week after Citic made a takeover bid for the company.
Johnson & Johnson is trading an undisclosed sum for private drugmaker Novira Therapeutics, picking up an early-stage treatment for hepatitis B and a handful of antivirals.
Big Biotechs Gilead Sciences and Biogen may both need to make acquisitions soon. But Vertex Pharmaceuticals is determined not to be one of their targets.
Shares of Zoetis were up more than 5% by midday Tuesday to $46.45, after the company topped an acquisition announcement by posting better-than-expected earnings. On Monday night, Zoetis said it would purchase Norway-based Pharmaq, a maker of vaccines for farmed fish, for $765 million. The next morning, the company announced that even though revenues were flat in the third quarter, its net income jumped 14% year over year to $189 million, or 38 cents per share.
Animal health leader Zoetis--which has been the subject of many a pharma buyout rumor--is making a pickup of its own. Late Monday, the Pfizer spinoff announced an agreement to purchase Pharmaq--which specializes in vaccines and pharmaceuticals for farmed fish--for $765 million.
Pfizer admits it's wooing Allergan for a merger worth more than $100 billion. But what it's not saying publicly is that GlaxoSmithKline has rejected its advances. That's the word from the Financial Times, whose sources say Pfizer had been flirting with a GSK buy, but the U.K.-based drugmaker wasn't impressed. Pfizer duly backed away.
The deal of the year could be arranged by Thanksgiving, or so goes the story. Despite opposition from politicians, despite the tricky nature of pulling off a tax inversion that size, Pfizer and Allergan may well be engaged before the month is out, giving Pfizer its long-sought tax reduction and its answer to the who-will-you-buy question that's popped up on every earnings call since AstraZeneca's final rejection last year.
Bristol-Myers Squibb is acquiring private biotech Cardioxyl Pharmaceuticals in a deal that could be worth more than $2 billion, bringing in a Phase II treatment for heart failure.
Want to dodge some competition for your fast-growing products? Buy it up. That's the tack Shire took Monday, agreeing to shell out $5.9 billion for Massachusetts-based Dyax. The company boasts on-the-market Kalbitor, an acute treatment for hereditary angioedema (HAE), as well as the Phase III-ready candidate DX-2930, which bears the FDA's fast track and breakthrough tags, as well as orphan drug designations in both the U.S. and EU.
Shire signed a deal to buy Dyax for $5.9 billion, planning to snatch up a smaller competitor and fortify its rare disease business without taking its eyes off of acquisition target Baxalta.